These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36031544)

  • 21. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
    Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
    Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Types of non-viral delivery systems of small interfering RNA].
    Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
    Mol Biol (Mosk); 2012; 46(3):387-401. PubMed ID: 22888629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
    Joo MK; Yhee JY; Kim SH; Kim K
    J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor targeted methotrexate and small interfering RNA co-delivery.
    Steinborn B; Truebenbach I; Morys S; Lächelt U; Wagner E; Zhang W
    J Gene Med; 2018 Jul; 20(7-8):e3041. PubMed ID: 29949222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery.
    Whitehead KA; Sahay G; Li GZ; Love KT; Alabi CA; Ma M; Zurenko C; Querbes W; Langer RS; Anderson DG
    Mol Ther; 2011 Sep; 19(9):1688-94. PubMed ID: 21750531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural modification of siRNA for efficient gene silencing.
    Lee SJ; Son S; Yhee JY; Choi K; Kwon IC; Kim SH; Kim K
    Biotechnol Adv; 2013; 31(5):491-503. PubMed ID: 22985697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanovector delivery of siRNA for cancer therapy.
    Shen H; Sun T; Ferrari M
    Cancer Gene Ther; 2012 Jun; 19(6):367-73. PubMed ID: 22555511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Action and reaction: the biological response to siRNA and its delivery vehicles.
    Kanasty RL; Whitehead KA; Vegas AJ; Anderson DG
    Mol Ther; 2012 Mar; 20(3):513-24. PubMed ID: 22252451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
    Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
    Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knocking down barriers: advances in siRNA delivery.
    Whitehead KA; Langer R; Anderson DG
    Nat Rev Drug Discov; 2009 Feb; 8(2):129-38. PubMed ID: 19180106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
    Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
    Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.
    Akhtar S
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1347-62. PubMed ID: 20929276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
    Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
    Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
    Martirosyan A; Olesen MJ; Howard KA
    Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.
    Lu M; Zhang M; Hu B; Huang Y
    Methods Mol Biol; 2021; 2282():77-100. PubMed ID: 33928571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.
    Zhao W; Zhang Y; Jiang X; Cui C
    Drug Des Devel Ther; 2016; 10():3851-3865. PubMed ID: 27920500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.
    Adesina SK; Akala EO
    Mol Pharm; 2015 Dec; 12(12):4175-87. PubMed ID: 26524196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.